1. Home
  2. INGR vs GRFS Comparison

INGR vs GRFS Comparison

Compare INGR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingredion Incorporated

INGR

Ingredion Incorporated

N/A

Current Price

$97.86

Market Cap

6.0B

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

SELL

Current Price

$7.66

Market Cap

4.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
INGR
GRFS
Founded
1906
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
4.9B
IPO Year
1997
2008

Fundamental Metrics

Financial Performance
Metric
INGR
GRFS
Price
$97.86
$7.66
Analyst Decision
Hold
Buy
Analyst Count
7
2
Target Price
★ $119.50
$10.87
AVG Volume (30 Days)
★ 606.0K
434.4K
Earning Date
11-05-2026
07-28-2022
Dividend Yield
★ 3.41%
1.14%
EPS Growth
★ 15.14
N/A
EPS
★ 4.01
N/A
Revenue
★ $7,219,000,000.00
N/A
Revenue This Year
N/A
$2.15
Revenue Next Year
$1.96
$6.22
P/E Ratio
$24.28
★ $18.67
Revenue Growth
N/A
★ N/A
52 Week Low
$93.72
$6.96
52 Week High
$123.49
$9.90

Technical Indicators

Market Signals
Indicator
INGR
GRFS
Relative Strength Index (RSI) 51.21 58.74
Support Level $94.04 $7.61
Resistance Level $104.60 $8.36
Average True Range (ATR) 1.75 0.15
MACD 0.46 0.04
Stochastic Oscillator 69.29 90.83

Price Performance

Historical Comparison
INGR
GRFS

About INGR Ingredion Incorporated

Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Share on Social Networks: